- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05848453
Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses
February 8, 2024 updated by: Bacoba AG
A Phase 1, Double Blind, Randomized, Placebo-Controlled First in Human Study, to Assess the Safety, Tolerability and Pharmacokinetics of BAP5191 Following Topical Application of Repeat Doses in Healthy Adult Participants
All enrolled participants will be randomized to 3 cohorts with 8 participants each and will receive BAP5191 and placebo topically on a square of 121 cm2 each in the left and right scapula region daily for 28 days, with a 28-d safety follow-up.
The squares will be covered with a semi-occlusive patch. The doses will escalate from Cohort 1 to Cohort 2 to Cohort 3.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Adams, PhD
- Phone Number: +41 (78) 734 0078
- Email: adams@bacoba.ch
Study Contact Backup
- Name: Alessandra Zizzari, PhD
- Email: zizzari@bacoba.ch
Study Locations
-
-
-
Basel, Switzerland
- Universität Basel Departement Klinische Forschung Ambulantes Studienzentrum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Healthy adult participants,18 to 65 years of age.
- Women of childbearing potential (WOCBP) must agree to use a highly effective form of contraception, from at least 7 days prior to first administration to 28 days after last administration.
- Male participants with WOCBP partner must be willing to use condoms from first IMP application to 90 days after last application.
- Body Mass Index (BMI) between 18 and 29.9 kg/m2. Body weight must be greater than 50 kg.
- Clinical laboratory parameters, vital signs, pulse oximetry, and ECG within the reference range from population studies, or showing no clinically relevant deviations.
Key Exclusion Criteria:
- Chronic use of immunosuppressants within 3 years prior to the first administration of the study drug.
- History of prior leishmaniasis or extensive travel to endemic regions within 1 year prior to the first administration of the study drug.
- Presence or history of severe adverse reaction to any drug, or sensitivity to components of the study medication or to adhesive bandages or tape.
- Skin diseases, excessive hair, tattoos, pigmentation, scars or moles that could interfere with patch application and skin assessment at the site of application.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
1 mg/mL (0.1%) BAC6027 formulation; placebo
|
Placebo
|
Experimental: Cohort 2
5 mg/mL (0.5%) BAC6027 formulation; placebo
|
Placebo
|
Experimental: Cohort 3
10 mg/mL (1.0%) BAC6027 formulation; placebo
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General safety (number, frequency, severity, seriousness and duration of adverse events)
Time Frame: From day 0 to day 55
|
Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events, treatment emerging adverse events.
|
From day 0 to day 55
|
Heart rate from baseline
Time Frame: From day 0 to day 55
|
Change of pulse rate from baseline.
|
From day 0 to day 55
|
Respiratory rate from baseline
Time Frame: From day 0 to day 55
|
Change of respiratory rate from baseline.
|
From day 0 to day 55
|
Temperature from baseline
Time Frame: From day 0 to day 55
|
Change of tympanic temperature from baseline.
|
From day 0 to day 55
|
ECG parameters from baseline
Time Frame: From day 0 to day 55
|
Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline.
|
From day 0 to day 55
|
Blood pressure from baseline
Time Frame: From day 0 to day 55
|
Change of blood pressure from baseline.
Systolic and diastolic blood pressure will be assessed.
|
From day 0 to day 55
|
Local skin tolerability: dermal response score
Time Frame: From day 0 to day 55
|
Summarized statistics of tolerability assessment based on dermal response score and other effects score.
The dermal response score ranges from score 0 (better, No evidence of irritation) to score 7 (worse, Strong reaction spreading beyond test site).
|
From day 0 to day 55
|
Local skin tolerability: other effects score
Time Frame: From day 0 to day 55
|
Summarized statistics of tolerability assessment based on dermal response score and other effects score.
The other effects score ranges from score 0 (better, None observed) to score 4 (worse, Glazing with fissures, Film of dried serous exudates covering all or part of the patch site, Small petechial erosions and/or scabs).
|
From day 0 to day 55
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of BAC6027
Time Frame: during the procedure, day 0 - day 31
|
Peak Plasma Concentration (Cmax) of BAC6027, if detectable.
|
during the procedure, day 0 - day 31
|
Tmax of BAC6027
Time Frame: during the procedure, day 0 - day 31
|
Time to reach Cmax (Tmax), in case of plasma concentration determined.
|
during the procedure, day 0 - day 31
|
AUC of BAC6027
Time Frame: during the procedure, day 0 - day 31
|
Area under the curve (AUC) of the plasma concentration determined.
|
during the procedure, day 0 - day 31
|
AUC (0-t), of BAC6027
Time Frame: during the procedure, day 0 - day 31
|
Concentration from time zero to the last quantifiable concentration at time t, in case plasma concentration can be determined.
|
during the procedure, day 0 - day 31
|
T1/2 of BAC6027
Time Frame: during the procedure, day 0 - day 31
|
The plasma elimination half-life, In case plasma concentration can be determined.
|
during the procedure, day 0 - day 31
|
AUC (0-∞) of BAC6027
Time Frame: during the procedure, day 0 - day 31
|
The AUC of the plasma concentration from time zero to infinity with extrapolation of the terminal phase, In case plasma concentration can be determined.
|
during the procedure, day 0 - day 31
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histopathological findings of skin biopsies taken after completion of treatment on Day 31.
Time Frame: after the last PK sample collection, Day 31.
|
Description of histopathological observations by application site and dose administered.
|
after the last PK sample collection, Day 31.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2023
Primary Completion (Estimated)
March 15, 2024
Study Completion (Estimated)
March 15, 2024
Study Registration Dates
First Submitted
March 27, 2023
First Submitted That Met QC Criteria
April 27, 2023
First Posted (Actual)
May 8, 2023
Study Record Updates
Last Update Posted (Actual)
February 12, 2024
Last Update Submitted That Met QC Criteria
February 8, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- BAP5191-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet